Single- and multiple-dose pharmacokinetics, potential for CYP3A inhibition, and food effect in patients with cancer and healthy subjects receiving ipatasertib

ConclusionIpatasertib exhibited rapid absorption and was dose-proportional over a broad dose range. Ipatasertib appeared to be a moderate CYP3A inhibitor when administered at 600  mg and could be administered with or without food in clinical studies.Trail registrationNCT01090960 (registered March 23, 2010); NCT02536391 (registered August 31, 2015).
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research

Related Links:

Condition:   Gastric Cancer Intervention:   Diagnostic Test: 68Ga-FAPI-04 PET/CT and 18F-FDG PET/CT Sponsor:   Ruijin Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Dr Mark Kris discusses a recent trial demonstrating improved disease-free survival for patients with resected stage II to IIIA, PD-L1-positive lung cancer treated with atezolizumab following cisplatin-based chemotherapy.Medscape Oncology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news
ConclusionsThis study highlights the combined action of sleep problems and physical activity on fatigue during the onset of induction chemotherapy. These two parameters could represent meaningful intervention targets to improve a patient ’s status during chemotherapy.Trial registrationThe study was registered on the WHO trial register (DRKS00007824).
Source: Supportive Care in Cancer - Category: Cancer & Oncology Source Type: research
ConclusionThe identification and removal of the barriers related to HCPs and HCSM in  routine care are crucial. Education of and communication with cancer patients and their family caregivers are two important pillars in the quality of intravenous chemotherapy (IV CT) and this education and communication should be based on individualized care and tailored to the unique needs of eac h patient.
Source: Supportive Care in Cancer - Category: Cancer & Oncology Source Type: research
Source: Supportive Care in Cancer - Category: Cancer & Oncology Source Type: research
This study retrospectively analyzed the risk factors for transchemotherapy dysgeusia.MethodsBefore each chemotherapy cycle, patients were routinely evaluated for the presence/severity of dysgeusia based on the Common Terminology Criteria for Adverse Events (CTCAE) v5.0 scale for adverse effects and graded as follows: 0, no change in taste; 1, altered taste with no impact on eating habits; or 2, altered taste with an impact on eating habits. Information from 2 years of evaluations was collected and patient medical records were reviewed to obtain data on chemotherapy cycle, sex, age, body mass index, body surface area, prima...
Source: Supportive Care in Cancer - Category: Cancer & Oncology Source Type: research
Am J Physiol Gastrointest Liver Physiol. 2021 Dec 1. doi: 10.1152/ajpgi.00060.2021. Online ahead of print.ABSTRACTHepatocellular carcinoma (HCC) is the most common primary liver cancer, which is not sensitive to radiotherapy and chemotherapy and very often experiences postoperative relapse. In this regard, effective screening of liver cancer is considered as the most important and urgent task. The aim of our study was to determine whether N-methyl-D-aspartate receptor (NMDAR) and, in particular, its subunits, can serve as biomarkers to distinguish the precancerous liver at early stages of liver fibrosis. We assessed the de...
Source: American Journal of Physiology. Gastrointestinal and Liver Physiology - Category: Physiology Authors: Source Type: research
Source: Cancer Management and Research - Category: Cancer & Oncology Tags: Cancer Management and Research Source Type: research
.To explore lived time of women with ovarian cancer during chemotherapy.
Source: European Journal of Oncology Nursing - Category: Cancer & Oncology Authors: Source Type: research
The current standard-of-care for the treatment of advanced non-small cell lung cancer (NSCLC) incorporates targeted therapies, immune-checkpoint inhibitors (ICI) and systemic chemotherapy. Antibody-drug conjugates (ADC) are a class of anti-cancer therapy capable of transporting cytotoxic drugs directly to tumour cells, thus harnessing the strengths of both cytotoxic chemotherapy and targeted therapy.In this review we provide a comprehensive review the design, mode of action, and mechanisms of resistance to ADCs in NSCLC.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Drugs & Pharmacology | Study